C WorldWide Group Holding A S Acquires 100,000 Shares of Insmed, Inc. $INSM

C WorldWide Group Holding A S grew its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 62.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 261,110 shares of the biopharmaceutical company’s stock after acquiring an additional 100,000 shares during the period. Insmed accounts for approximately 0.7% of C WorldWide Group Holding A S’s portfolio, making the stock its 25th largest holding. C WorldWide Group Holding A S owned 0.12% of Insmed worth $27,840,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its stake in shares of Insmed by 65.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 263 shares during the period. First Trust Advisors LP boosted its stake in Insmed by 80.8% in the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock worth $4,770,000 after purchasing an additional 21,176 shares during the period. Baird Financial Group Inc. purchased a new position in Insmed during the 2nd quarter valued at about $2,589,000. Amundi grew its holdings in Insmed by 21,194.4% during the 2nd quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock valued at $1,130,000 after buying an additional 11,445 shares in the last quarter. Finally, Natixis bought a new stake in shares of Insmed during the second quarter valued at about $1,072,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on INSM shares. JPMorgan Chase & Co. lowered their price target on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Friday, July 17th. Roth Capital reaffirmed a “buy” rating on shares of Insmed in a report on Monday, June 8th. Mizuho set a $192.00 target price on shares of Insmed in a research note on Tuesday, June 16th. Finally, UBS Group reissued a “buy” rating and issued a $172.00 price target on shares of Insmed in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $205.52.

Insmed Stock Performance

Insmed stock opened at $124.89 on Wednesday. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The stock has a market cap of $27.27 billion, a P/E ratio of -30.39 and a beta of 0.82. The firm’s fifty day moving average price is $116.65 and its 200-day moving average price is $124.70.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm’s quarterly revenue was up 296.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.70) earnings per share. On average, equities research analysts expect that Insmed, Inc. will post -1.83 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Michael Smith sold 1,806 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the completion of the transaction, the insider directly owned 37,648 shares in the company, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the transaction, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 273,753 shares of company stock worth $35,604,764. 2.10% of the stock is currently owned by corporate insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.